Therabel to market Javelin's Dyloject in Europe
This article was originally published in Scrip
Executive Summary
Therabel Pharma has taken exclusive European marketing rights to Javelin Pharmaceuticals' Dyloject (intravenous diclofenac sodium). The deal is worth up to $71 million in upfront, sales and regulatory milestone payments, and double-digit sales royalties, to the US company.